Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ALXO
SELLALX Oncology Holdings Inc. · Healthcare · United States · $273M · Avg Vol: $3M/d
COMPANY DESCRIPTION
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company dedicated to developing novel therapies that block the CD47 checkpoint pathway to enhance the immune system's attack on cancer. Its lead product candidate, ALX148, is designed as a potent CD47 blocker with an improved safety profile, positioning the company as a focused innovator in a challenging yet high-potential oncology therapeutic area.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -0.92 | -1.39 | -1.02 | -0.77 | — | -1.35 | -0.65 | -0.54 | — |
| Shares | 134.6M | 134.6M | 134.6M | 134.6M | 0.0% | 134.6M | — | — | — |
| Debt | 9.4M | 9.6M | 9.9M | 9.7M | 1.3% | 13.0M | — | — | — |
| Equity | 263.5M | 189.7M | 113.6M | 26.0M | -53.8% | — | — | — | — |
| Op CF | -89.2M | -130.4M | -121.9M | -84.1M | — | -78.1M | — | — | — |
| Inv CF | -235.4M | 44.7M | 86.3M | 82.6M | — | — | — | — | — |
| Fin CF | 9.9M | 59.3M | 30.8M | 0.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ALXO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ALXO | ALX Oncology Holdings Inc.(you) | $273M | 31 | SELL |
| ELDN | Eledon Pharmaceuticals, Inc. | $276M | 33 | SELL |
| OABI | OmniAb, Inc. | $294M | 30 | SELL |
| SABS | SAB Biotherapeutics, Inc. | $268M | 28 | SELL |
| FATE | Fate Therapeutics, Inc. | $281M | 26 | SELL |
| XFOR | X4 Pharmaceuticals, Inc. | $363M | 32 | SELL |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $308M | 27 | SELL |
| PALI | Palisade Bio, Inc. | $339M | 28 | SELL |
| CCCC | C4 Therapeutics, Inc. | $376M | 33 | SELL |
| VNDA | Vanda Pharmaceuticals Inc. | $312M | 26 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%